S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
S&P 500   4,356.45 (-1.22%)
DOW   34,297.73 (-0.19%)
QQQ   345.11 (-2.32%)
AAPL   159.78 (-1.14%)
MSFT   288.49 (-2.66%)
FB   300.15 (-2.77%)
GOOGL   2,538.70 (-2.96%)
AMZN   2,799.72 (-3.15%)
TSLA   918.40 (-1.25%)
NVDA   223.24 (-4.48%)
BABA   119.14 (-1.02%)
NIO   23.79 (-4.34%)
AMD   111.13 (-4.63%)
CGC   7.36 (-0.54%)
MU   80.72 (-2.69%)
GE   91.11 (-5.98%)
T   26.48 (+0.53%)
F   19.98 (-2.01%)
DIS   136.51 (-0.69%)
AMC   16.02 (-3.73%)
PFE   52.54 (+1.94%)
ACB   4.21 (-2.55%)
BA   204.10 (-0.05%)
NASDAQ:VLON

Vallon Pharmaceuticals Stock Forecast, Price & News

$4.86
-0.17 (-3.38%)
(As of 01/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.60
$5.38
50-Day Range
$4.02
$8.00
52-Week Range
$3.61
$10.36
Volume
122,652 shs
Average Volume
183,353 shs
Market Capitalization
$33.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive VLON News and Ratings via Email

Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Vallon Pharmaceuticals logo

About Vallon Pharmaceuticals

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Headlines

12 Penny Stocks Most Popular on Reddit and Robinhood
December 12, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VLON
Phone
N/A
Fax
N/A
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
$100 thousand

Profitability

Net Income
$-4.82 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$33.11 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/25/2022
Next Earnings (Estimated)
4/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

807th out of 1,416 stocks

Pharmaceutical Preparations Industry

386th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Vallon Pharmaceuticals (NASDAQ:VLON) Frequently Asked Questions

Is Vallon Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vallon Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Vallon Pharmaceuticals stock.
View analyst ratings for Vallon Pharmaceuticals
or view top-rated stocks.

Are investors shorting Vallon Pharmaceuticals?

Vallon Pharmaceuticals saw a decline in short interest during the month of December. As of December 15th, there was short interest totaling 265,400 shares, a decline of 63.5% from the November 30th total of 727,400 shares. Based on an average daily volume of 745,500 shares, the short-interest ratio is presently 0.4 days. Currently, 8.3% of the shares of the stock are sold short.
View Vallon Pharmaceuticals' Short Interest
.

When is Vallon Pharmaceuticals' next earnings date?

Vallon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Vallon Pharmaceuticals
.

How were Vallon Pharmaceuticals' earnings last quarter?

Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) posted its earnings results on Friday, November, 12th. The company reported ($0.18) EPS for the quarter.
View Vallon Pharmaceuticals' earnings history
.

What price target have analysts set for VLON?

1 analysts have issued 1-year price targets for Vallon Pharmaceuticals' stock. Their forecasts range from $12.00 to $12.00. On average, they expect Vallon Pharmaceuticals' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 146.9% from the stock's current price.
View analysts' price targets for Vallon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vallon Pharmaceuticals' key executives?

Vallon Pharmaceuticals' management team includes the following people:
  • Mr. David C. Baker, CEO, Pres & Director (Age 58, Pay $339.9k)
  • Ms. Penny S. Toren, Sr. VP of Regulatory Affairs & Program Management (Age 54, Pay $242.05k)
  • Ms. Leanne M. Kelly, CFO & Principal Accounting Officer (Age 44) (LinkedIn Profile)
  • Dr. Timothy M. Whitaker, Chief Medical Officer (Age 62)

When did Vallon Pharmaceuticals IPO?

(VLON) raised $15 million in an IPO on Wednesday, February 10th 2021. The company issued 1,700,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is Vallon Pharmaceuticals' stock symbol?

Vallon Pharmaceuticals trades on the NASDAQ under the ticker symbol "VLON."

How do I buy shares of Vallon Pharmaceuticals?

Shares of VLON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vallon Pharmaceuticals' stock price today?

One share of VLON stock can currently be purchased for approximately $4.86.

How much money does Vallon Pharmaceuticals make?

Vallon Pharmaceuticals has a market capitalization of $33.11 million and generates $100 thousand in revenue each year.

How many employees does Vallon Pharmaceuticals have?

Vallon Pharmaceuticals employs 2 workers across the globe.

What is Vallon Pharmaceuticals' official website?

The official website for Vallon Pharmaceuticals is www.vallon-pharma.com.

Where are Vallon Pharmaceuticals' headquarters?

Vallon Pharmaceuticals is headquartered at TWO LOGAN SQUARE 100 N. 18TH STREET SUITE 300, PHILADELPHIA PA, 19103.

How can I contact Vallon Pharmaceuticals?

Vallon Pharmaceuticals' mailing address is TWO LOGAN SQUARE 100 N. 18TH STREET SUITE 300, PHILADELPHIA PA, 19103. The company can be reached via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.